Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Exhibit 99.1
Regencell Bioscience Holdings Limited Announces
At-the-Market Offering of Ordinary Shares
HONG KONG, March 30, 2026 – Regencell
Bioscience Holdings Limited (Nasdaq: RGC) (the “Company”), today announced that it has filed a prospectus supplement with
the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell an aggregate of up to $500,000,000
of its ordinary shares, par value $0.00001 per share (“Ordinary Shares”) from time to time through an at-the-market equity
offering program (“ATM Offering”). In addition, Company announced that it has entered into a sales agreement with Univest
Securities, LLC as its sales agent (the “Sales Agent”) to sell its Ordinary Shares in this ATM Offering from time to time.
Sales of our Ordinary Shares, if any, in the
ATM Offering under the prospectus supplement and the accompanying prospectus may be made by any method that is deemed an “at-the-market
offering” as defined in Rule 415 under the Securities Act of 1933, as amended, including, without limitation, sales made directly
on or through the Nasdaq Capital Market, to or through a market maker or otherwise, and/or other methods permitted by law, including in
privately negotiated transactions, in each case at market prices prevailing at the time of sale or at prices related to such prevailing
market prices. As a result, sales prices may vary.
The Company is not obligated to sell any Ordinary Shares under the
ATM Offering. The Sales Agent will use commercially reasonable efforts to sell the Ordinary Shares from time to time, based upon instructions
from the Company. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The timing of any sales
will depend on a variety of factors to be determined by the Company.
The Company currently intends to use the net proceeds from the ATM
Offering primarily for working capital, capital expenditures and general corporate purposes.
The Ordinary Shares will be offered under the Company’s
shelf registration statement on Form F-3 (File No. 333-294722), which was filed with the Securities and Exchange Commission (the
“SEC”) on March 30, 2026 and became automatically effective upon filing. A prospectus supplement related to the ATM
Offering (File No. 333-294722) was filed with the SEC by the Company on March 30, 2026. Prospective investors should read the
prospectus included in the registration statement on Form F-3, the prospectus supplement and other documents the Company has filed
with the SEC (some of which are incorporated by reference into the prospectus and prospectus supplement) for more complete
information about the Company and the ATM Offering. Electronic copies of the prospectus supplement and the accompanying prospectus
relating to the ATM Offering may be obtained without charge by visiting the SEC’s website at www.sec.gov or by contacting
Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.
This press release does not constitute an offer to sell or the solicitation
of an offer to buy any securities of the Company, nor will there be any sales of such securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Regencell Bioscience Holdings Limited
We are an early-stage bioscience company that focuses on research,
development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically
Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. Our goal is to save and improve the lives of the patients, their
families and caregivers and become a market leader for natural and holistic treatments for neurological disorders globally.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify some of these forward-looking statements
by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,”
“continue” or other similar expressions. Statements that are not historical facts, including statements about the Company’s
beliefs and expectations, are forward-looking statements. Among other things, the business outlook from management in this press release,
as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written
or oral forward-looking statements in its periodic reports to the SEC on Forms 20-F and Form 6-K, in its annual reports to shareholders,
in its and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking
statements involve inherent risks and uncertainties.
A number of factors could cause actual results to differ materially
from those contained in any forward-looking statement, including but not limited to the following: the Company’s goals and strategies;
the Company’s future business development, financial condition and results of operations; changes in the Company’s expenditures;
general economic and business conditions globally; and assumptions underlying or related to any of the foregoing.
Further information regarding these and other risks is included in
the Company’s annual report on Form 20-F and current report on Form 6-K and other documents filed with the SEC. All information
provided in this press release is as of the date hereof, and the Company does not undertake any obligation to update any forward-looking
statement, except as required under applicable laws.
CONTACT:
Regencell Bioscience Holdings Limited Investor Relations
James Chung
ir@rgcbio.com
SOURCE:
Regencell Bioscience Holdings Limited
